Quotient Diagnostics Ltd.
This article was originally published in Start Up
Executive Summary
Quotient Diagnostics is among the latest group of contenders betting that its diagnostic system can displace existing ones and grow the market for point-of-care diabetes testing. The firm is pinning its hopes not only on a new sort of chemical-binding technology, but more importantly on the incorporation of that science into a diagnostic system that the company claims is simpler, lighter, and smaller than competing point-of-care offerings.